Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 1819479
Drug: Matching placebo
First Posted Date
2022-07-22
Last Posted Date
2023-04-05
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
24
Registration Number
NCT05469646
Locations
🇯🇵

SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan

A Study in Healthy Men to Test How Esomeprazole Influences the Amount of BI 1819479 in the Blood

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 1819479
Drug: Esomeprazole
First Posted Date
2022-07-20
Last Posted Date
2023-01-26
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
15
Registration Number
NCT05467475
Locations
🇩🇪

Humanpharmakologisches Zentrum Biberach, Biberach, Germany

Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease

First Posted Date
2022-07-19
Last Posted Date
2023-09-11
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
30400
Registration Number
NCT05465317
Locations
🇺🇸

Duke Clinical Research Institute, Durham, North Carolina, United States

A Study in Healthy Men to Test Whether BI 474121 Can Reverse the Memory Problems Caused by Ketamine

First Posted Date
2022-07-11
Last Posted Date
2022-08-01
Lead Sponsor
Boehringer Ingelheim
Registration Number
NCT05451095

A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery

First Posted Date
2022-07-06
Last Posted Date
2023-12-29
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
2
Registration Number
NCT05446129
Locations
🇺🇸

Mount Sinai School of Medicine, New York, New York, United States

A Study to Test How Healthy Women Tolerate Different Doses of BI 1819479

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI matching placebo
Drug: BI 1819479
First Posted Date
2022-07-01
Last Posted Date
2023-08-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
62
Registration Number
NCT05440799
Locations
🇩🇪

CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

A Study in Healthy People to Compare 2 Different Formulations of BI 1015550 Taken With or Without Food

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 1015550 ICF
Drug: BI 1015550 TF2
First Posted Date
2022-06-23
Last Posted Date
2022-10-05
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
13
Registration Number
NCT05428436
Locations
🇩🇪

Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study in Healthy Men to Test How BI 456906 is Processed in the Body

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 456906 (C-14)
First Posted Date
2022-06-16
Last Posted Date
2022-12-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
6
Registration Number
NCT05421338
Locations
🇳🇱

ICON, Groningen, Netherlands

Alteplase Treatment in Elderly Acute Ischaemic Stroke (AIS) Patients

Completed
Conditions
Stroke
Interventions
Drug: rt-PA
First Posted Date
2022-06-02
Last Posted Date
2024-10-17
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
3058
Registration Number
NCT05401149
Locations
🇨🇳

Boehringer Ingelheim (China) Investment Co., ltd., Shanghai, China

Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan

First Posted Date
2022-06-02
Last Posted Date
2024-08-09
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
17018
Registration Number
NCT05402020
Locations
🇨🇳

National Tawain University Hospital, Taipei, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy